| Submission of formal petitions and representations to PMDA [Pharmaceuticals and Medical Devices Agency] and the MHLW [Mōrōshō – Ministry of Health, Labour and Welfare]. | 患者权益倡导
> 患者权益倡导 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100 | National | Sometimes | 119036459439 |
| Towards the approval of molecularly targeted therapies. | 癌症
> 癌症：肺 | 监管合作伙伴关系
> 为营销授权申报做出贡献 | 1,000 | Regional | Rarely | 119053044699 |
| We submit a formal petition to the [Japanese] Ministry of Health, Labour and Welfare (MHLW) once a year and conduct a follow-up meeting. | 移植
> 移植：最多 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100 | National | Regularly | 119051955551 |
| I participate in petition campaigns through the National Psoriasis Patients Federation. | 皮肤
> 银屑病 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | Regional | Rarely | 119013683256 |
| Every year, we submit budget requests for the following fiscal year to the national government and prefectural governments. | 肝脏
> 肝脏疾病：大多数类型 | 影响政策和立法
> 影响医疗保健政策和立法 | 5,000 | National | Regularly | 119036457777 |
| We have organised vaccine awareness marches and submitted formal written requests to the Kōrōshō [厚生労働省 – Ministry of Health, Labour and Welfare]. | 传染性
> 传染病：其他 | 影响政策和立法
> 参与公众听证会和咨询 | 100 | National | Sometimes | 119035140720 |
| We submit a formal written petition to the MHLW [Mōsō Rōdōshō – Ministry of Health, Labour and Welfare] once a year. | 移植
> 移植：最多 | 影响政策和立法
> 参与公众听证会和咨询 | 100 | National | Regularly | 119051955551 |
| Once a year, the organisation submits its formal requests at the opinion exchange forum held jointly with the prefectural and municipal authorities. | 风湿性
> 风湿性疾病：其他 | 影响政策和立法
> 参与公众听证会和咨询 | 100 | National | Regularly | 119078001121 |
| Visited the House of Representatives members' office building and held a meeting with a member of parliament. | 风湿性
> 风湿性疾病：大多数类型 | 影响政策和立法
> 动员议员和政治领导人 | 1,000 | National | Rarely | 119014930939 |
| Submission of a written petition to the Minister of Health, Labour and Welfare. | 内分泌
> 糖尿病：1型 | 影响政策和立法
> 动员议员和政治领导人 | 100,000 | National | Regularly | 119019815441 |
| Expedited approval of stem cell-based regenerative medicine products. | 稀有
> 罕见病：EB | 影响政策和立法
> 解决医疗保健中的障碍/异常问题 | 1,000 | National | Sometimes | 119077906981 |
| Early approval of new medicines, resolution of drug lag and drug loss, and applications based on established medical knowledge. | 癌症
> 癌症：胰腺癌 | 影响政策和立法
> 解决医疗保健中的障碍/异常问题 | 10,000 | National | Regularly | 119079604807 |
| Insurance reimbursement coverage for Pegasys [peginterferon alfa-2a, used to treat chronic hepatitis B and C, as well as rare cancers]. | 癌症
> 癌症：血液 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 1,000 | National | Regularly | 119014697897 |
| We have organised vaccine awareness marches and submitted formal written requests to the Kōrōshō [厚生労働省 – Ministry of Health, Labour and Welfare]. | 传染性
> 传染病：其他 | 定价与可负担性倡导
> 参与宣传活动 | 100 | National | Sometimes | 119035140720 |
| A request for greater disease awareness. | 未指定
> 未指定 | 定价与可负担性倡导
> 参与宣传活动 | 100 | National | Regularly | 119061457501 |
| Towards the approval of molecularly targeted therapies [for lung cancer]. | 癌症
> 癌症：肺 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | Regional | Rarely | 119053044699 |
| Key advocacy priorities include: accelerated approval pathways for new medicines, resolution of drug lag and drug loss issues, and the known-use application process (applications for medicines already recognised in the scientific literature or approved in other jurisdictions). | 癌症
> 癌症：胰腺癌 | 改善访问路径
> 促进公平获取药品/医疗保健 | 10,000 | National | Regularly | 119079604807 |
| We have organised vaccine awareness marches and submitted formal written requests to the Kōrōshō [厚生労働省 – Ministry of Health, Labour and Welfare]. | 传染性
> 传染病：其他 | 改善访问路径
> 倡导更广泛的疫苗获取渠道 | 100 | National | Sometimes | 119035140720 |
| Insurance reimbursement coverage for Pegasys [peginterferon alfa-2a, used to treat chronic hepatitis B and C, as well as rare cancers]. | 癌症
> 癌症：血液 | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | 1,000 | National | Regularly | 119014697897 |
| Expedited approval of stem cell-based regenerative medicine products. | 稀有
> 罕见病：EB | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | 1,000 | National | Sometimes | 119077906981 |
| The Ministry of Health, Labour and Welfare; the Medical Insurance Subcommittee of the Social Security Council; and related bodies. | 过敏
> 过敏 | 机构治理
> 确保在政府咨询机构中的代表性 | 100,000 | National | Sometimes | 119078144899 |
互动
行动与倡导
4 提及
